Titlebook: Biopharmaceutical Applied Statistics Symposium; Volume 2 Biostatisti Karl E. Peace,Ding-Geng Chen,Sandeep Menon Book 2018 Springer Nature S

涌出

书目名称Biopharmaceutical Applied Statistics Symposium影响因子(影响力)




书目名称Biopharmaceutical Applied Statistics Symposium影响因子(影响力)学科排名




书目名称Biopharmaceutical Applied Statistics Symposium网络公开度




书目名称Biopharmaceutical Applied Statistics Symposium网络公开度学科排名




书目名称Biopharmaceutical Applied Statistics Symposium被引频次




书目名称Biopharmaceutical Applied Statistics Symposium被引频次学科排名




书目名称Biopharmaceutical Applied Statistics Symposium年度引用




书目名称Biopharmaceutical Applied Statistics Symposium年度引用学科排名




书目名称Biopharmaceutical Applied Statistics Symposium读者反馈




书目名称Biopharmaceutical Applied Statistics Symposium读者反馈学科排名

Glower

Assignment

biosphere

Advancing Interpretation of Patient-Reported Outcomes,ion of the patient’s response by a clinician or anyone else. In this chapter methods of PRO interpretation are discussed, under the assumption that a PRO instrument has already evidenced validity and reliability, in order to lend meaning and import to PRO scores. Specifically, we focus on three ways

Kindle

maroon

革新

Missing Data,ore the end of a trial or a laboratory test that cannot be obtained. Depending on why and how much data are missing, the results and interpretability of the trial can be jeopardized. Fortunately, there is a vast literature about statistical methods that can handle missing data. Probably the most imp

Myelin

Bayesian Subgroup Analysis with Hierarchical Models,ion. To address this unwanted variation, we consider Bayesian hierarchical modeling of subgroups. When considered exchangeable in a one-way hierarchical structure, the subgroup treatment effects have posterior means that shrink the sample estimates toward the overall estimate. The amount of shrinkag

Commodious

,A Question-Based Approach to the Analysis of Safety Data,f focus in both the pre-marketing drug development and post-approval life cycle management phases. In the pre-market setting, the primary safety information comes from clinical trials data covering several domains and other supporting information, such as, safety pharmacology, toxicology, historical

sinoatrial-node